Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Amsterdam, the Netherlands.
Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Oral Oncol. 2022 Feb;125:105698. doi: 10.1016/j.oraloncology.2021.105698. Epub 2021 Dec 29.
The aim was to analyse prognosticators in acinic cell carcinoma (AciCC) in two head and neck referral centers in Amsterdam, the Netherlands.
Eighty- nine cases of AciCC treated between 1979 and 2016 were retrospectively reviewed. Five, - 10 -and 20- year estimates of survival were executed as well as univariate analysis of prognosticators.
The majority of AciCC were T1-T2; 89%. Two percent had nodal disease (2%). The most affected organ was the parotid gland (84%) with a female preponderance (67%). Mean age was 52 years with most cases diagnosed in the fourth to sixth decade. The majority of patients received adjuvant radiotherapy. Elective neck dissection (END) in the N0 neck showed no metastases. High grade transformation (HGT) was found in 21% of cases. Median follow up was 101.9 months. Median time to recurrence was 26 months. Nine patients developed distant metastases (DM) of whom 6 had HGT-AciCC. Median survival with DM was 7 months. Five,- ten -and twenty- year estimates were 84%, 81% and 81% for recurrence free survival respectively. Negative clinical features were advanced stage disease and tumour size > 2.6 cm. Negative histological features were a high mitotic rate, HGT, close and involved surgical margins and necrosis.
AciCC- HGT excluded- of the head and neck has an excellent prognosis and shows acceptable long term results. END can be considered as part of the standard treatment due to the relative high incidence of HGT- AciCC and low accuracy of cytology.
目的是在荷兰阿姆斯特丹的两个头颈部转诊中心分析腺泡细胞癌(AciCC)的预后因素。
回顾性分析了 1979 年至 2016 年间治疗的 89 例 AciCC 病例。进行了 5 年、10 年和 20 年的生存估计,并进行了预后因素的单因素分析。
大多数 AciCC 为 T1-T2;89%。有 2%的患者有淋巴结疾病(2%)。受影响最严重的器官是腮腺(84%),女性患病率较高(67%)。平均年龄为 52 岁,大多数病例在第四至第六个十年诊断。大多数患者接受了辅助放疗。在 N0 颈部进行选择性颈清扫术(END)未发现转移。21%的病例发现高级别转化(HGT)。中位随访时间为 101.9 个月。中位复发时间为 26 个月。9 例患者发生远处转移(DM),其中 6 例有 HGT-AciCC。发生 DM 后的中位生存时间为 7 个月。无复发生存率的 5 年、10 年和 20 年估计值分别为 84%、81%和 81%。阴性临床特征为晚期疾病和肿瘤大小>2.6cm。阴性组织学特征为高有丝分裂率、HGT、切缘接近和受累以及坏死。
排除头颈部 AciCC-HGT 的患者预后良好,显示出可接受的长期结果。由于 HGT-AciCC 的相对高发和细胞学的准确性较低,END 可被视为标准治疗的一部分。